NCT04409275 (INC-CVD-202001) is a clinical trial in Pulmonary Fibrosis, sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

Who is sponsoring NCT04409275?

NCT04409275 is sponsored by Fundación para la Investigación del Hospital Clínico de Valencia.

What condition does NCT04409275 study?

NCT04409275 studies Pulmonary Fibrosis.

Is NCT04409275 still recruiting?

NCT04409275 is currently status unknown. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT04409275: INC-CVD-202001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

Status unknown Last updated 11 June 2020

What this trial tests

trial in Pulmonary Fibrosis in 500 participants. Status unknown.

Timeline

21 May 2020

Primary endpoint
31 December 2020

31 July 2021

Quick facts

Lead sponsor	Fundación para la Investigación del Hospital Clínico de Valencia
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	21 May 2020
Primary completion	31 December 2020
Estimated completion	31 July 2021
Sites	1 location across Spain

Conditions studied

Pulmonary Fibrosis — all drugs for Pulmonary Fibrosis →

Sponsor

Fundación para la Investigación del Hospital Clínico de Valencia

Who can join

Adults 18 to 90, any sex, with Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after hospital discharge.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Lung function and radiological findings 1 year after COVID-19: a prospective follow-up.
Tarraso J, Safont B, Carbonell-Asins JA, Fernandez-Fabrellas E, et al · · 2022 · cited 58× · PMID 36096801 · DOI 10.1186/s12931-022-02166-8
Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months After Hospital Discharge.
Safont B, Tarraso J, Rodriguez-Borja E, Fernández-Fabrellas E, et al · · 2022 · cited 58× · PMID 34497426 · DOI 10.1016/j.arbres.2021.08.014
Biomarkers of Fibrosis in Patients with COVID-19 One Year After Hospital Discharge: A Prospective Cohort Study.
Mulet A, Tarrasó J, Rodríguez-Borja E, Carbonell-Asins JA, et al · · 2023 · cited 17× · PMID 36848314 · DOI 10.1165/rcmb.2022-0474oc
Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge.
Botello-Marabotto M, Tarrasó J, Mulet A, Presa-Fernández L, et al · · 2025 · cited 1× · PMID 40088077 · DOI 10.1002/jmv.70289
Predictors of Progression in Pre-COPD: The 3P Study Rationale and Design.
González-Villaescusa C, Tarrasó Castillo J, Martínez-Pitarch D, Riesco Miranda JA, et al · · 2026 · PMID 41438363 · DOI 10.1016/j.opresp.2025.100519

Verify or expand the search:

Other recruiting trials for Pulmonary Fibrosis

Currently open trials in the same condition.

NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07396467 — Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis · active not recruiting
NCT06912659 — The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis W · active not recruiting
NCT06685874 — Interstitial Lung Disease Exacerbations Study · active not recruiting
NCT06532071 — Advanced Imaging for Pulmonary Fibrosis · Phase 2 · recruiting

Other Fundación para la Investigación del Hospital Clínico de Valencia trials

Trials by the same sponsor.

NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
NCT07291999 — Tissue Characterization in STEMI Using Cardiac MRI: a Multicenter Registry · active not recruiting
NCT06655532 — Effects of an Exercise Program in Women Over 60 yr. With HFpEF and Sarcopenia on Functional Capacity and Quality of Life · NA · not yet recruiting
NCT06578078 — A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients · Phase 3 · recruiting
NCT06578520 — Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04409275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación para la Investigación del Hospital Clínico de Valencia
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04409275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing